Key result
Increased cardiac aldosterone worsened cardiac hypertrophy by 41% in hypertensive mice by inhibiting atrial natriuretic peptide expression, an effect prevented by eplerenone.
Why the study?
Does aldosterone inhibition with eplerenone or ANP infusion prevent cardiac hypertrophy and fetal gene expression changes in hypertensive mice with cardiac hyperaldosteronism?
Population
Double-transgenic mice with cardiac hyperaldosteronism and systemic hypertension, along with Ren and AS…
Comparison
Eplerenone or ANP infusion (for one month) vs Untreated AS-Ren mice or respective controls
Design
Preclinical
Follow-up
1 month (for ANP infusion)
Authors
Loading...
Should not change clinical practice; leaves open whether cardiac aldosterone drives human hypertrophy via ANP.
Does aldosterone inhibition with eplerenone or ANP infusion prevent cardiac hypertrophy and fetal gene expression changes in hypertensive mice with cardiac hyperaldosteronism?
Effect estimate: +41%
p-value: p=<0.05
Increased cardiac aldosterone worsens cardiac hypertrophy in hypertensive mice by inhibiting ANP expression and altering fetal gene programs, effects which are prevented by mineralocorticoid receptor antagonism.
Azibani et al. (2012) studied Arterial hypertension and cardiac hypertrophy. Eplerenone vs. Untreated mice was evaluated on Cardiac hypertrophy (worsening in AS-Ren vs Ren mice) (+41%, p=<0.05). Increased cardiac aldosterone worsened cardiac hypertrophy by 41% in hypertensive mice by inhibiting atrial natriuretic peptide expression, an effect prevented by eplerenone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: